{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:12:58Z","timestamp":1793502778567,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00535-019-01571-z","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T16:04:09Z","timestamp":1553789049000},"page":"939-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer"],"prefix":"10.1007","volume":"54","author":[{"given":"Shuwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"1571_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3322\/caac.21395","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics. CA Cancer J Clin. 2017;67:177\u201393.","journal-title":"CA Cancer J Clin"},{"key":"1571_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"1571_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40259-013-0073-y","volume":"28","author":"BS Seal","year":"2014","unstructured":"Seal BS, Sullivan SD, Ramsey SD, et al. Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database. BioDrugs. 2014;28:229\u201336.","journal-title":"BioDrugs"},{"key":"1571_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290\u2013314.","journal-title":"Cancer"},{"key":"1571_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0006-2952(03)00260-0","volume":"66","author":"S Faivre","year":"2003","unstructured":"Faivre S, Chan D, Salinas R, et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol. 2003;66:225\u201337.","journal-title":"Biochem Pharmacol"},{"key":"1571_CR6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013\u20139.","journal-title":"J Clin Oncol"},{"key":"1571_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med"},{"key":"1571_CR8","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697\u2013705.","journal-title":"J Clin Oncol"},{"key":"1571_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/tpj.2012.31","volume":"13","author":"E Cecchin","year":"2013","unstructured":"Cecchin E, D\u2019Andrea M, Lonardi S, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil\/leucovorin\/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013;13:403\u20139.","journal-title":"Pharmacogenomics J."},{"key":"1571_CR10","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1158\/1535-7163.MCT-14-0636","volume":"14","author":"E Martinez-Balibrea","year":"2015","unstructured":"Martinez-Balibrea E, Martinez-Cardus A, Gines A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 2015;14:1767\u201376.","journal-title":"Mol Cancer Ther"},{"key":"1571_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1383-5742(02)00009-1","volume":"511","author":"C Bernstein","year":"2002","unstructured":"Bernstein C, Bernstein H, Payne CM, et al. DNA repair\/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 2002;511:145\u201378.","journal-title":"Mutat Res"},{"key":"1571_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1101\/gad.13.7.768","volume":"13","author":"WL Laat de","year":"1999","unstructured":"de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13:768\u201385.","journal-title":"Genes Dev"},{"key":"1571_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00280-014-2562-1","volume":"74","author":"Z Li","year":"2014","unstructured":"Li Z, Qing Y, Guan W, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol. 2014;74:777\u201386.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1571_CR14","doi-asserted-by":"publisher","first-page":"9990","DOI":"10.1093\/nar\/gks818","volume":"40","author":"EM McNeil","year":"2012","unstructured":"McNeil EM, Melton DW. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res. 2012;40:9990\u201310004.","journal-title":"Nucleic Acids Res"},{"key":"1571_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/carcin\/21.4.551","volume":"21","author":"RM Lunn","year":"2000","unstructured":"Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000;21:551\u20135.","journal-title":"Carcinogenesis"},{"key":"1571_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/carcin\/21.5.965","volume":"21","author":"EJ Duell","year":"2000","unstructured":"Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 2000;21:965\u201371.","journal-title":"Carcinogenesis"},{"key":"1571_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/FPC.0b013e3283415124","volume":"21","author":"MY Huang","year":"2011","unstructured":"Huang MY, Huang ML, Chen MJ, et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genom. 2011;21:18\u201325.","journal-title":"Pharmacogenet Genom"},{"key":"1571_CR18","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","volume":"28","author":"HL McLeod","year":"2010","unstructured":"McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010;28:3227\u201333.","journal-title":"J Clin Oncol"},{"key":"1571_CR19","doi-asserted-by":"publisher","first-page":"11478","DOI":"10.1038\/ncomms11478","volume":"7","author":"M Wang","year":"2016","unstructured":"Wang M, Gu D, Du M, et al. Common genetic variation in ETV6 is associated with colorectal cancer susceptibility. Nat Commun. 2016;7:11478.","journal-title":"Nat Commun"},{"key":"1571_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279\u201384.","journal-title":"Behav Brain Res"},{"key":"1571_CR21","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1158\/1078-0432.CCR-05-1363","volume":"12","author":"V Moreno","year":"2006","unstructured":"Moreno V, Gemignani F, Landi S, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006;12:2101\u20138.","journal-title":"Clin Cancer Res"},{"key":"1571_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/tpj.2015.8","volume":"15","author":"EJ Kap","year":"2015","unstructured":"Kap EJ, Seibold P, Richter S, et al. Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer. Pharmacogenomics J. 2015;15:505\u201312.","journal-title":"Pharmacogenomics J"},{"key":"1571_CR23","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.18632\/oncotarget.7352","volume":"7","author":"F Wang","year":"2016","unstructured":"Wang F, Zhang SD, Xu HM, et al. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer. Oncotarget. 2016;7:11724\u201332.","journal-title":"Oncotarget."},{"key":"1571_CR24","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s00018-009-8737-y","volume":"66","author":"T Nouspikel","year":"2009","unstructured":"Nouspikel T. DNA repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell Mol Life Sci. 2009;66:994\u20131009.","journal-title":"Cell Mol Life Sci"},{"key":"1571_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3324\/haematol.2013.093500","volume":"99","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99:511\u20138.","journal-title":"Haematologica"},{"key":"1571_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12013-013-9530-y","volume":"67","author":"Y Dahai","year":"2013","unstructured":"Dahai Y, Sanyuan S, Hong L, et al. A relationship between replication protein A and occurrence and prognosis of esophageal carcinoma. Cell Biochem Biophys. 2013;67:175\u201380.","journal-title":"Cell Biochem Biophys"},{"key":"1571_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/gcc.22171","volume":"53","author":"M Hoxha","year":"2014","unstructured":"Hoxha M, Fabris S, Agnelli L, et al. Relevance of telomere\/telomerase system impairment in early stage chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2014;53:612\u201321.","journal-title":"Genes Chromosomes Cancer"},{"key":"1571_CR28","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1111\/j.1464-410X.2010.09828.x","volume":"108","author":"G Levidou","year":"2011","unstructured":"Levidou G, Gakiopoulou H, Kavantzas N, et al. Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma. BJU Int. 2011;108:E59\u201365.","journal-title":"BJU Int."},{"key":"1571_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/0092-8674(95)90289-9","volume":"80","author":"A Aboussekhra","year":"1995","unstructured":"Aboussekhra A, Biggerstaff M, Shivji MK, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell. 1995;80:859\u201368.","journal-title":"Cell"},{"key":"1571_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/1400","volume":"5","author":"T Ikegami","year":"1998","unstructured":"Ikegami T, Kuraoka I, Saijo M, et al. Solution structure of the DNA- and RPA-binding domain of the human repair factor XPA. Nat Struct Biol. 1998;5:701\u20136.","journal-title":"Nat Struct Biol"},{"key":"1571_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s12013-014-9995-3","volume":"70","author":"Z Di","year":"2014","unstructured":"Di Z, Sanyuan S, Hong L, et al. Enhanced radiosensitivity and G2\/M arrest were observed in radioresistant esophageal cancer cells by knocking down RPA expression. Cell Biochem Biophys. 2014;70:887\u201391.","journal-title":"Cell Biochem Biophys"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01571-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-019-01571-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01571-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T08:34:05Z","timestamp":1607070845000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-019-01571-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s00535-019-01571-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"19 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}